HC Wainwright & Co. Reiterates Buy on Trevi Therapeutics, Maintains $21 Price Target
Benzinga Newsdesk 8 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Brandon Folkes reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $21 price target.
HC Wainwright & Co. analyst Brandon Folkes reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $21 price target.